v3.26.3
Acquisition - Schedule of Pro Forma (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Business Combination [Line Items]        
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests $ (21,695) $ 2,369 $ 98,223 $ 36,981
Kashiv        
Business Combination [Line Items]        
Net revenue 862,918 793,555 2,386,897 2,216,607
Net income (loss) 8,411 (22,748) 61,380 (43,119)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests $ (11,351) $ (38,511) $ 13,922 $ (84,498)